



PB 32 of 2025

National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 3) 2025

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 March 2025

REBECCA RICHARDSON

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments	2
<i>National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)</i>	2

1 Name

- (1) This instrument is the *National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 3) 2025*.
- (2) This instrument may also be cited as PB 32 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 April 2025.	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 85AB(1) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1 Schedule 1, after item dealing with Amino acid formula with carbohydrate without phenylalanine

Insert:

Amino acid formula with fat, carbohydrate, vitamins and minerals without phenylalanine

2 Schedule 1, after item dealing with Molnupiravir

Insert:

Momelotinib

3 Schedule 1, after item dealing with Propantheline

Insert:

Propylene glycol

4 Schedule 1, after item dealing with Tioguanine

Insert:

Tislelizumab

5 Schedule 1, after item dealing with Tofacitinib

Omit:

Tolvaptan

6 Schedule 2, after item dealing with Salbutamol

Insert:

Sacubitril with valsartan

7 Schedule 2, after item dealing with Tocilizumab

Insert:

Tolvaptan